ArticleProceedings of the National Academy of Sciences of the United States of America2018
Structural basis for the regulation of β-glucuronidase expression by human gut Enterobacteriaceae.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 64 citations in OpenAlex.
- In vitro inhibition of Escherichia coli β-glucuronidase by aripiprazole.Pharmacological reports : PR · 2026Article
- Short-term temporal variation in the early-life gut microbiota links maternal clinical phenotypes to neonatal jaundice.BMC microbiology · 2026Article
- Beyond estrobolome 1.0: unraveling endocrine-microbiome axis as a driver and therapeutic target in hormone-driven cancers.NPJ biofilms and microbiomes · 2026Review
- Molecular basis of antibiotic sensing by the TetR family regulator CecR - a structural perspective.The FEBS journal · 2026Article
- EefR mutations drive sanguinarine resistance by activating cryptic multidrug efflux pumps in AcrB-NullVirulence · 2025Article
- Hyperprolactinemia and Brain Health: Exploring the Gut-Brain Axis and Therapeutic Strategies.Molecular neurobiology · 2025Review
- Bacteria-Based Roles in Solid Tumors: Potential for Prevention and Treatment.Pathogens (Basel, Switzerland) · 2025Review
- Orally Administered Drugs and Their Complicated Relationship with Our Gastrointestinal Tract.Microorganisms · 2024Review
- A New Paradigm in the Relationship between Gut Microbiota and Breast Cancer: β-glucuronidase Enzyme Identified as Potential Therapeutic Target.Pathogens (Basel, Switzerland) · 2023Review
- Sex, puberty, and the gut microbiome.Reproduction (Cambridge, England) · 2023Review
- Metabolically-targeted dCas9 expression in bacteria.Nucleic acids research · 2023Article
- Genomic and phenotypic characterization of multidrug-resistantFrontiers in microbiology · 2023Article
- Effect of endocrine disruptors on bacterial virulence.Frontiers in cellular and infection microbiology · 2023Review
- Allergic Inflammation: Effect of Propolis and Its Flavonoids.Molecules (Basel, Switzerland) · 2022Review
- Pharmacological hypothesis: A recombinant probiotic for taming bacterial β-glucuronidase in drug-induced enteropathy.Pharmacology research & perspectives · 2022Article
- The role of gut microbial β-glucuronidase in drug disposition and development.Drug discovery today · 2022Review
- Decreased Tissue Omega-6/Omega-3 Fatty Acid Ratio Prevents Chemotherapy-Induced Gastrointestinal Toxicity Associated with Alterations of Gut Microbiome.International journal of molecular sciences · 2022Article
- Gonococcal Clinical Strains Bearing a CommonmBio · 2022Article
- Article
- Draft Genome Sequences ofMicrobiology resource announcements · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The gut microbiota harbor diverse β-glucuronidase (GUS) enzymes that liberate glucuronic acid (GlcA) sugars from small-molecule conjugates and complex carbohydrates. However, only the Enterobacteriaceae family of human gut-associated Proteobacteria maintain a GUS operon under the transcriptional control of a glucuronide repressor, GusR. Despite its potential importance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.